Table 1.
Flow cytometry analysis of P-gp functional activity with R123 or JC-1 in A549, HepG2, and MCF-7 cells.
| Sample | Intracellular accumulation of JC-1 and R123 (%) | ||
|---|---|---|---|
| A549 | HepG2 | MCF-7 | |
| R123 | 100.0 ± 5.1 | 100.0 ± 7.2 | 100.0 ± 6.2 |
| R123 + V | 70.6 ± 7.2 | 124.89 ± 3.7* | 110.8 ± 3.9 |
| R123 + DOX | 129.7 ± 3.6* | 126.88 ± 9.2* | 148.2 ± 8.3∗+ |
| R123 + ACL | 111.2 ± 5.9 | 157.29 ± 6.5∗+ | 137.7 ± 11.7∗+ |
| JC-1 | 100.0 ± 2.9 | 100.0 ± 4.7 | 100.0 ± 8.6 |
| JC-1 + V | 85.2 ± 5.6 | 212.41 ± 5.2* | 161.2 ± 8.9* |
| JC-1 + DOX | 92 ± 5.5 | 250 ± 2.9∗+ | 386.8 ± 13.3∗+ |
| JC-1 + ACL | 86.9 ± 13.9 | 212.59 ± 7.0∗+ | 158.3 ± 14.6* |
Results represent means ± SD of 4 independent experiments. *P < 0.05, significant differences between P-gp functional activity calculated from influx of R123 or JC-1 and R123 or JC-1 plus Verapamil and from R123 or JC-1 plus ACL or DOX after a 30-minute period of time monitoring the transport of fluorescence probes to the cells. + P < 0.05, significant differences between positive control samples (cells preincubated with Verapamil) and cells treated with DOX or ACL. P-gp functional activity was evaluated based on the basis of fluorescence ratios of R123 or JC-1 (Figure 4) and calculated for each tested probe. The final results were presented as percentage values.